Alternative Data for Spero Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 9 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,737 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Spero Therapeutics
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
| Price | $2.45 |
| Target Price | Sign up |
| Volume | 377,519 |
| Market Cap | $130M |
| Year Range | $1.83 - $3.04 |
| Dividend Yield | 0% |
| PE Ratio | 10.75 |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative BuyFebruary 10 - SeekingAlpha |
 |
3 Promising Penny Stocks With Market Caps Up To $300MJanuary 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 3M | 0 | 3M | -7.4M | -7.4M | -0.130 |
| Q2 '25 | 12M | 0 | 12M | -1.7M | -2.4M | -0.030 |
| Q1 '25 | 5.9M | 14M | -7.7M | -14M | -15M | -0.247 |
| Q4 '24 | 15M | 95M | -80M | -21M | -21M | -0.367 |
| Q3 '24 | 13M | 2,000 | 13M | -17M | -19M | -0.320 |
Insider Transactions View All
| Keutzer Timothy filed to sell 742,506 shares at $2.4. February 9 '26 |
| Rajavelu Esther filed to sell 1,062,907 shares at $2.4. February 9 '26 |
| Rajavelu Esther filed to sell 1,012,091 shares at $2.4. February 9 '26 |
| Keutzer Timothy filed to sell 761,158 shares at $2.2. February 5 '26 |
| Keutzer Timothy filed to sell 764,629 shares at $2.1. February 5 '26 |
Similar companies
Read more about Spero Therapeutics (SPRO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Spero Therapeutics
The Market Cap of Spero Therapeutics is $130M.
As of today, Spero Therapeutics' PE (Price to Earnings) ratio is 10.75.
Currently, the price of one share of Spero Therapeutics stock is $2.45.
The SPRO stock price chart above provides a comprehensive visual representation of Spero Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Spero Therapeutics shares. Our platform offers an up-to-date SPRO stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Spero Therapeutics (SPRO) does not offer dividends to its shareholders. Investors interested in Spero Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Spero Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
